Introduction
Rhe umatoid arthritis (RA) is an inflammatory autoimmune disease of unknow n etiology. 1 -3 It is know n that this inflammatory dise ase affe cts the synovial me mbrane s of various joints and that there is de n o vo vascularization be ne ath the synovial lining along w ith an orchestrate d infiltration of the joint by T and B lymphoc ytes as w ell as macrophage s (Mø). Se veral investigators have re ported the as sociation of Mø w ith the pathology of RA. 4 -7 More over, it has be en re porte d that 80-100% of those c ells w hich line the synovium are Mø. 8 In addition to the Mø, ne utrophils are abundant in the synovial fluid and it has be en re porte d that both c ell types are found in a state of he ighte ne d ac tivation . 2,3 ,8 It has re ce ntly be en re porte d that Mø directly influenc e a ne utrophil-depe nde nt inflammatory re sponse and that the ne utrophil, in turn, re c ruits and ac tivates Mø. 9 Along w ith the pre se nce of the above c ell type s, it is doc ume nte d that there are abnormal le vels of numerous cytokines in an RA joint. 1, 8 Among the cytokines pre se nt are the follow ing: tumor ne crosis fac tor a (TNFa ), IL-1, IL-6, IL-8 as w e ll as others. 7 ,10 ,1 1 How e ver, of the cytokines re porte d to be pre sent in the RA joint, TNFa is be lie ve d to be pivotal to the disease proc ess. 1, 7 Sinc e TNFa initiat es a c as cade of pro-inflammatory cytokines, 7 ,1 0,1 1 the central role of this cytokine in the disease proc ess is not surprising. Se ve ral investigators have re ported that the primary sourc e of TNFa in an RA joint is the Mø; 12 ,13 how e ver, the factor(s) w hich are re sponsible for stimulation of these cells to se cre te TNFa have not be ide ntifie d.
Since it has be e n re porte d that ne utrophils are abundant in the synovial fluid of the RA joint, 2 ,3 ,5 one w ould also ex pe ct myeloperox idase (MPO) to be pre sent. In fac t, other inve stigators have docume nte d the pre senc e of enzymatically ac tive MPO as w e ll as 16-29 m g/ml of enzymatically inac tive MPO in RA joints . 14 ,15 These studie s indicate that both forms of the enzyme may be associated w ith RA.
In other studies complete d in this laboratory, data indicated that re c ombinant human MPO and e nzymatically inactive MPO e nhanc ed the follow ing re side nt murine Mø functions: (1) re spiratory burst, 16 ,17 (2) se cre tion of TNFa , IL-6, IL-8, and granulocyte-Mø colony stimulating factor (GM-CSF) (unpublishe d data), and (3) phagoc ytosis and intra ce llular killing of Ca n d ida a lbica n s and E. c o li. 1 6 -1 8 Mye loperox idase also induce d ele vated titers of TNFa and IFN a /b in v ivo . 19 Since it has be e n re ported that ne utrophils, MPO, e nzymatic ally inactive MPO, and Mø are pre se nt in an inflamed RA joint, the pre se nt study w as undertake n to dete rmine if the interaction be tw e en either MPO or enzymatic ally inactive MPO and Mø could contribute to the 'chronicity' of inflammation associated w ith ex pe rimental RA. A Lew is rat model w as employe d to investigate the effe ct of ne utrophilic MPO on ex ace rbation of this disease. The dise as e w as induc ed using a single intra-artic ular inje ction of stre ptococc us A c ell w all fragme nts (PG-APS). After development of ex perime ntal RA, e ithe r porcine MPO or partially inactivated porc ine MPO w as injec te d into the same joint to dete rmine w hat effect this enzyme had on ex ac erbation of the disease . For c onve nienc e, in the re mainde r of this manuscript, RA w ill be use d to designate mono-articular ex pe rime ntal RA unle ss othe rw is e state d.
Materials and Methods

Myeloperoxidase
The use of rat MPO w ould have be en pre fe rre d, but it w as not available . Highly purified p orcine MPO w as gene rously provide d by Dr R.C. Allen. The mannose content of this pre p aration w as 4.6% and it c ontaine d 1539 units/ml of activity using o -dianisidine as a substrate . Cathepsin G, a serine prote ase , has be en re porte d to be pre se nt in ne utrophils. Trypsin, anothe r se rine proteas e, w as used to ge ne rate inactive MPO as follow s: Mye lope rox idase w as p artially inac tivated by ex p osure to trypsin-Se pharose 4B gel slurry (Worthington Biochemic als, Fre ehold, NJ). Prior to mix ing the MPO and the gel slurry together, a 1:12 dilution of MPO w as he ate d to 70°C for 10 min. Afte r the solution c ooled to be low 37°C, the diluted MPO w as mix e d w ith the slurry at a 4:1 ratio of MPO to trypsin for the digestion. Dige stion w as allow ed to proce ed for 6 h at 37°C. Afte r this incubation, the supe rnatant w as c ollec te d, aliquote d, and store d at -20°C until used. This pre paration of MPO ex hibite d 123 units/ml of ac tivity as me asured by o -dianisidine. For the re mainder of this manusc ript, the partially inactivate d MPO w ill be re ferred to as iMPO.
Animals
Age matched female Lew is rats w e ighing approximately 180 g w ere obtaine d from Harlan Sprague Daw le y, Indianapolis, IN. Animals w ere cared for and house d in a facility according to the guideline s of the Animal Welfare Ac t.
Reagents
The 
Cells
Reside nt rat peritone al Mø w e re c ollec te d by peritone al lavage similar to the proce dure pre viously desc ribed by the pre se nt investigators. 1 7,1 8 Brie fly, after the c ell suspens ion w as re moved from the abdominal c avity and ce ntrifuge d at 1000 rpm for 10 min at 4°C, re d blood ce lls w e re lyse d using hypotonic phosphate buffe re d saline (PBS). After ce ntrifugation, the supernatants w ere de cante d and the peritone al ce lls dilute d to 1.2 3 10 6 c ells/ml and re suspended in Dulbec co's modifie d Eagle's me dium (Gibc o, Long Island, NY) c ontainin g HEPES (Sigma), sodium bicarbonate, and gentamic in sulfate (Sigma). Subse quent to a 2-hour inc ubation, monolayers w ere w ashe d vigorously w ith media to re move non-adherent cells. Using staining procedures, it w as dete rmine d that the adhe re nt cell c ultures w ere 99% pure Mø. Subsequently, Mø monolaye rs w e re ex posed to differe nt conce ntrations of e ithe r MPO or iMPO. After various inc ubation pe riods, supernantant s w ere c ollec te d and store d at -70°C until used. ELISA kits for TNFa w e re purchas ed from Ge nzyme (Cambridge, MA), and the manufac turer's instruc tions w e re follow ed.
Arthritis Model
Fe male Lew is rats w ere used for the induc tion of a mono-artic ular arthritis. The right ankle joint (w hich w as the ne gative c ontrol) w as inje cte d w ith 10 m l of normal saline . The left ankle joint (w hich w as the ex pe rimental joint) w as initially injecte d w ith 10 m l of a ste rile, aque ous suspe nsion of PG-APS (a gene rous gift from Dr S. Lichtman, Univers ity of North Carolina, Chapel Hill, NC) containin g a dose equivalent to 2 m g of rhamnose .
20 ,21 A 27 gauge 0.5 inch ne edle w as inse rted though the Achilles te ndon above the calc ane ous into the vic inity of the tibiotalar joint. For all injections, the animals w e re sedated by e ther inhalation .
After IA injec tion of PG-APS, the joints inc re as ed in diame te r by approx imately 1-2 mm (5.8 to 7.0-8.0 mm) w ithin 24 -48 h. Over a period of 7-21 days, the se joints de cre ase d in sw elling to approximately 6.5 mm. Since no furthe r de cre ase in diamete r w as note d ove r a period of 2 months, 6.5 mm w as cons idere d to be 'base line' le vel of sw e lling. Therefore , w hen a PG-APS tre ated joint measured 6.5 mm, both ankle joints w ere re -injec te d: the right joint re c eived 10 m l of normal saline, and the le ft joint re c eived 10 m l of various tre atment solutions. Those joints w hich inc re ased in size by a minimum of 0.5 mm 24 -48 hours after re -inje ction w e re considere d positive for inflammation. On a daily basis, the peri-articular sw e lling of both treate d and c ontrol ankle joints w as monitore d. The pe ri-artic ular sw e lling w as measured w ith a calipe r starting on day zero, and continue d daily until the study w as c omple te d. 
Statistical analysis
A tw o-tailed Student's t-te st w as used to dete rmine significance be tw een groups. Most data are pre se nte d as the mean ± S.E.M.
Results
Sinc e it is know n that TNFa is pivotal to human RA and initiate s a cascade of pro-inflammatory cytokines, initial ex perime nts w ere done to de te rmine if either MPO or iMPO could induce TNFa sec re tion by Mø in v itro . Ex posure of re sident rat peritone al Mø to either MPO or iMPO induced markedly higher tite rs of TNFa than that obtain ed from the control cultures. It can be note d from Fig. 1 that iMPO induced a dosedepende nt incre ase in TNFa secre tion w ith peak titers be ing obtained at 6 h. If, how e ve r, MPO w as employed, an inc re ase in TNFa w as observe d w ith 20 m g/ml but not w ith 0.2 m g/ml. At the highe st conc entration (20 m g), MPO induc ed approx imately 50% less cytokine than iMPO (data not show n). It should be noted that the level of endotox in in the most c oncentrated pre paration of e ithe r MPO or iMPO employed in these studies containe d £ 8 3 10 -3 ng/ml. This leve l of e ndotox in did not induc e TNFa in vitro as de te rmined by ELISA (data not show n).
The nex t se t of ex perime nts w as done in v ivo to dete rmine if e ithe r form of the enzyme alone c ould initia te arthritis. Afte r an initial injec tion of saline, animals w e re injec te d w ee kly for 3 conse cutive w eeks w ith various c once ntration s of e ithe r MPO or iMPO. In addition, a non-spec ific prote in, mannosylated BSA, w as also te ste d. None of these substanc es initiate d the clinical symptoms of arthritis as noted by sw e lling and erythema. Also, since LPS c ontaminatio n is ubiquitous, and this substance ac tivates Mø, levels of e ndotox in (10 ng/joint) that w e re approx imately 1 3 10 5 time s higher than the conce ntration found in any of the solutions employed in this study w e re injecte d IA. The same re sults as that for other initiators w e re obtaine d, i.e. the re w e re no clinical symptoms of arthritis as dete rmine d by sw elling and erythema (data not show n).
Pe rp e tu a tio n o f infla m m a tio n a s s o cia te d w ith a rth ritis
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Induction of tumor necrosis factor-alpha (TNFa ) by enzymatically inactive myeloperoxidase (iMPO). Resident rat peritoneal macrophage (Mø) were cultured in a 96 well Costar plate. After a 2-hour incubation, the cells were washed, and either treatments or media alone were added. The supernatants from treated and control wells were collected and stored at -70°C until used for an ELISA. Manufacturer's instructions were followed.
Sinc e it had bee n establishe d that LPS at the above c onc entration could not in itia te arthritis, a numbe r of animals w e re inje cte d IA w ith LPS a fte r PG-APS tre atme nt. Whe n 10 ng/joint of LPS w e re inje cte d IA, the re w ere no clinic al symptoms obs erved. It should be note d that this cyc le w as re pe ated tw ic e w ith identic al re sults. Whe n 15 m g of BSA (a substanc e to w hich Lew is rats should not re spond) 2 3 w as re peatedly inje cte d IA afte r PG-APS, onc e again, no clinic al symp toms w e re obse rve d (data not show n).
Various conc entrations of eithe r MPO or iMPO w ere e mployed a fte r arthritis w as initiat ed w ith PG-APS. Conc entrations e mployed varie d be tw e en 0.2 and 20 m g in 10 m l. If 0.2 m g w as injec te d IA, approx imately 50% of the animals ex hibite d RA after each inje ction serie s. If 20 m g w ere employed, all animals deve loped RA w ith 66% displaying 'chronic' arthritis. That is, the joints did not re turn to 'baseline' sw e lling w ithin a 2 month pe riod afte r the initial MPO injection (data not show n). If 2 m g of MPO w ere injecte d after PG-APS, the initial re sponse w as not positive, w he re as, a sec ond injec tion ex ac erbate d a flare of the disease (Fig. 2a) . How eve r, w hen 2 m g of iMPO w e re inje cte d after PG-APS, all animals ex hibite d sw elling and erythema in the injecte d joints. This patte rn w as re peate d afte r a sec ond IA injection of iMPO w as administe re d (Fig. 2b) . Be cause of the above re sponse s, 2 m g/10 m l w e re e mployed for the re mainder of the study.
As state d pre viously, in vitro ex perime nts had demonstrate d that either MPO or iMPO c ould induc e TNFa . The re fore, ex periments w ere done to dete rmine if TNFa w as pivotal in the ex ace rbation of arthritis observe d after IA injections of either MPO or iMPO. After joints w e re inje cte d w ith PG-APS and sw e lling as w ell as e rythema had re turne d to 'baseline', IA inje ctions of MPO alone , iMPO alone , antiTNFa alone , MPO and anti-TNFa , or iMPO and antiTNFa w e re administe re d. Figure 3 de picts the re sults of an MPO+ anti-TNFa ex pe rime nt. The pre senc e of anti-TNF-a c omplete ly ablated the effect of MPO w ith re spect to ex acerbation of a flare of RA. Similar re sults w ere obtained w ith iMPO (data not show n).
Mye loperox idase is know n to be taken up by Mø via the Mø mannose re c eptor (MMR). those for mannans alone (Fig. 4) , i.e. no e ffec t. Similar re sults w e re obtaine d w ith iMPO (data not show n).
Histologic al ex aminations of joints w hich re ce ive d the various treatme nt modalities w ere done . Table 1 desc ribes the observations obtained. Minimal to no pathology w as note d in joints injec te d w ith saline. Minimal pathology did pers is t at 1 month after a single inje ction of PG-APS. If MPO w as employe d as an initia to r and inje cte d onc e a w ee k for 3 w ee ks at the high dose of 20 m g in 10 m l, the pathology observe d w as similar to that observed w ith a single injection of PG-APS alone (afte r 3 w e eks). That is: the pathology obse rved after three w ee ks w as agree able w ith w hat has be en observed pre viously in the model. How e ver, if RA w as initia te d w ith PG-APS and the joint w as subsequently injec te d w ith 20 m g of MPO, there w as ex te nsive pathology (Table 1) . If joints w ere injecte d once w ith PG-APS and the n w ith 2 m g in 10 m l of either MPO or iMPO, the pathology w as le ss se vere than that observe d w ith the higher dose of the enzyme. No marked differe nc e in pathology w as note d be tw e en animals inje cte d w ith 2 m g of either MPO or iMPO. The pre se nce of mannans diminished the overall pathology obse rved (Table 1) .
Mediators of
Since either MPO or iMPO induc ed clinical and pathologic al changes consiste nt w ith an ex a c e rbatio n of arthritis, immunoc ytochemistry studies w ere done to dete rmine if the Mø-like cells, w hich comprise the synovial lining of the inflamed joint, w ere a sourc e of TNFa . After initiation of RA w ith PG-APS and IA inje ction of either MPO or iMPO, animals w ere sacrificed and the joints pre pared for staining. 
Discussion
Numerous cell type s including ne utrophils, monocytes/Mø, and T c ells have be e n re ported to be pre sent in the synovial fluid of human RA joints .
4,6,1 0,2 6 Also, nume rous c ytokine s are found in the synovial fluid of inflame d joints.
2,7 ,1 1 Of all the cytokines pre sent in an RA joint, it is be lieved that TNFa is pivotal to the dise as e since it initiates a casc ade of cytokines assoc iate d w ith inflammation. 7 ,10 ,11 Tumor ne crosis fac tor a , induces the se cre tion of IL-1 7 ,10 ,1 1 as w e ll as activate s oste oclasts in RA joints. 7 ,11 More over, IL-1 causes loss of prote oglycan from articular c artilage w hich is one of the hallmarks of human RA. 4 The pre senc e of TNFa and IL-1 induces secre tion of IL-8 and GM-CSF, as w ell as an infiltration of both ne utrophils and monocyte s into an arthritic joint. 4 ,27 The c ytokine s, IL-1, TNFa and GM-CSF c ause ne utrophil de granulation 4,28 w hich w ould provide a c ontinuou s supply of both MPO and iMPO to the joint.
Ce lls of Mø lineage have be e n re ported to be the major source of TNFa in a human RA joint 6,11 ,29 and the inte nsity of additional Mø migration into the joint correlates w ith clinical activity of human RA. 6 When re sident rat peritone al Mø w ere ex pose d to e ithe r iMPO (Fig. 1) or MPO an incre ase in TNFa se cre tion w as observe d. Tumor ne crosis fac tor induc tion by iMPO w as dose depe ndent; how e ver, this w as not true w he n MPO w as employed. This c ould be ex plained in part by the follow ing: MPO induce d gre ate r amounts of re active ox ygen inte rmediates (ROI) than MPO (unpublished data), and that ROI can enhance sec re tion of a cytokine as w ell as ox idize re c eptors 3 0 pre venting ce ll signaling c ausing a re duction of se cre te d cytokine . Only at the highe st conc entration of MPO, w ere the Mø stimulated sufficie ntly to se cre te TNF. Thus, minimal ox idation by iMPO w ould re sult in greate r c ell signaling and conse que ntly higher tite rs of TNF (approx imately 2-fold). The se in v itro studie s suggest that both MPO and iMPO can inte rac t w ith Mø in the microenvironme nt of an arthritic joint.
It has be en e stablished that PMN's w ithin human RA synovial fluid degranulate and sec re te MPO into the mic roe nvironment. 5 Within 10 minutes of stimulation of ne utrophils, app rox imate ly 30% of the ir MPO is se cre te d. 31 Of the 30% of the se cre te d e nzyme , only 5% re tains enzymatic activity. 31 ,3 2 Re sults of other studies indicate that PMN's re le ase d approx imately 50% of their MPO at a site of inflammation. Also, w ith re spect to human RA, Davie s e t a l., re porte d the pre senc e of MPO in arthritic joints. 5 More ove r, Edw ards e t a l., have re porte d that there are 16-29 m g/ml of enzymatic ally inactive MPO in the synovial fluid of a human arthritic joint. 15 In the pre sent study, the injec tion of 2 m g/joint (200 m g/ml) of the e nzyme w as the standard c onc entration employed. Since there is not a conse nsus among the numerous studies complete d to date w ith re spec t to the amount of bo th MPO and iMPO in a human RA joint, c oncentrations utilize d in this study may w ell be w ithin 'pathological range'.
From 0.2-20 m g of MPO injecte d into a joint did not initia te RA w ithin 24 -48 h after inje ction, as dete rmine d by both clinic al and pathologic al c riteria. In this study, IA injec tions of e ithe r MPO or iMPO a fte r PG-APS induc ed arthritis. The fact that PG-APS, but not MPO or iMPO, could initiate arthritis could be ex plained in part by the fac t that PG-APS is a more pote nt induc er of TNFa . Also, it is possible that MPO, w hich is highly c onserve d in various spec ie s, is not highly immunoge nic. With re spec t to prolonge d pre senc e of this enzyme and the induction of RA, it has be e n re ported that highly cationic mole cules have be e n as sociated w ith re te ntion in joints and arthritogenic ity. 23 Re te ntion is be lie ve d to be due to the inte rac tion of the cationic molec ule w ith the ne gatively charged cartilage . 23 ,34 ,3 5 Since this study involve d re peate d inje ctions of various tre atments into a partic ular joint, there w as conc ern that the trauma alone of re peated inje ctions could induce inflammation associate d w ith RA. Therefore , BSA and/or saline w as re p eatedly injec te d into PG-APS treate d joints. The re sults indicate d that re pe ated inje ctions w e re not suffic ie nt to induc e marked clinic al or pathologic al changes (Table 1) .
Ex ace rbation of an arthritic flare can be induc ed by a number of ex ogenous substance s such as LPS (at higher doses than those e mployed in the pre se nt study) and microbial superantigens . 33 The purpose of 'c yc ling' the injec tions of either MPO or iMPO after an initial injec tion of PG-APS w as to simulate flare s of the disease w hich oc curs in patients (Figs 2a and b) . As state d pre viously, the first injec tion of MPO, after PG-APS, did not induce a positive flare w here as the first injection of iMPO did induc e an ex ace rbation of the disease. A possible ex planation for this could be the fact that MPO induces tissue damage through ROI. 3 0 There fore , the first injection w ould re sult in pre dominantly tissue damage and subse que nt immune ce ll re c ruitment. How e ver, w ith the se cond inje ction, immune cells w ould now be pre se nt in the joint and w ould induce higher titers of TNFa . With iMPO, an initial inje ction w ould favor induction of proinflammatory c ytokine s and rapid re c ruitment of immune c ells and not dire ct tissue damage due to ROI.
Shepherd and Hoidal re ported that MPO binds to Mø via a specific re ce ptor, the MMR. 24 The re fore , if either MPO or iMPO w as causing an ex ac erbation of ex pe rimental arthritis and contributin g to 'chronic ity' of the disease, then inhibiting the binding of this enzyme should ame liorate clinic al symptoms. When either MPO or iMPO w ere inje cte d simultane ously w ith mannans, there w as no ex ace rbation of c linic al disease (Fig. 4) providing evide nce for the importanc e of Mø-MMR-ne utrophil (i.e. MPO or iMPO) interaction. Pathology re ports c orroborate d these re sults (Table 1) . Since PG-APS is a polymer of ace tylate d mannose, the same conce pt w as applied to the mode l itself. If MMR-PG-APS interaction w as suffic ie nt to induc e RA, then via compe titive binding, mannans should diminish or p re vent the initiation of the disease. When PG-APS w as injecte d simultaneously w ith mannans, there w as no clinical re sponse observe d. Again this indic ates a ce ntral role of the Mø-MMR ligand inte rac tion in the induction of arthritis using this animal.
Synovial type A c ells, w hich are of Mø lineage , are a major sourc e of TNFa in arthritic joints. 8 Using immunocytoche mistry, TNFa w as found only among the mononucle ar phagoc ytic c ells of the lining of the joint, in pe rivasc ular areas, and in the pannus 22 of joints injec te d w ith PG-APS follow e d by injection of either MPO or iMPO. These re sults indicate that either MPO or iMPO inte rac ting w ith c ells of the synovial lining, w hich are of Mø-line age, induce the production of TNFa . Also, the pattern of TNFa staining parallels that obse rved in human RA.
Various investigators have re ported that T cells participate in the pathologic al eve nts of RA.
